Next Article in Journal
The Role of Omega-3 Fatty Acids in Developmental Psychopathology: A Systematic Review on Early Psychosis, Autism, and ADHD
Next Article in Special Issue
Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P1 Receptor Modulator in Healthy Subjects
Previous Article in Journal
Molecular and Genetic Determinants of Glioma Cell Invasion
Previous Article in Special Issue
Translational Aspects of Sphingolipid Metabolism in Renal Disorders
Article Menu
Issue 12 (December) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2017, 18(12), 2606;

Plasma Sphingolipids in Acute Pancreatitis

Department of Hygiene, Epidemiology and Ergonomics, Medical University of Bialystok, Mickiewicza 2c Street, 15-022 Bialystok, Poland
Department of Physiology, Medical University of Bialystok, Mickiewicza 2c Street, 15-222 Bialystok, Poland
Department of Gastroenterology and Internal Medicine, Medical University of Bialystok, Skłodowskiej MC 24a Street, 15-276 Bialystok, Poland
Department of Clinical Nutrition, Medical University of Białystok, Mieszka I 4b Street, 15-054 Bialystok, Poland
Author to whom correspondence should be addressed.
Received: 30 October 2017 / Revised: 26 November 2017 / Accepted: 27 November 2017 / Published: 4 December 2017
(This article belongs to the Special Issue Sphingolipids: Signals and Disease)
Full-Text   |   PDF [1031 KB, uploaded 4 December 2017]   |  


Acute pancreatitis (AP) is a prevalent gastrointestinal disorder associated with systemic inflammatory response syndrome and, in the case of severe AP, a mortality rate ranging from 36% to 50%. Standard clinical treatment of AP includes intensive hydration, analgesia, and management of complications. Unfortunately, the direct treatment of AP at the level of its molecular pathomechanism has not yet been established. Recent studies indicate that the sphingolipid signaling pathway may be one of the important factors contributing to the development of inflammation in pancreatic diseases. In the current study, we sought to investigate this promising route. We examined the plasma sphingolipid profile of 44 patients with acute pancreatitis, dividing them into three groups: mild, moderate and severe AP. Samples were collected from these groups at days 1, 3 and 7 following their hospital admission. We demonstrated significant changes in blood plasma sphingolipids in relation to the time course of AP. We also found an inhibition of de novo ceramide synthesis in mild and moderate AP. However, the most important and novel finding was a significant elevation in sphingosine-1-phosphate (S1P) (a downstream metabolite of ceramide) in mild AP, as well as a dramatic reduction in the lipid molecule content in the early stage (days 1 and 3) of severe AP. This strongly indicates that plasma S1P could serve as a prognostic marker of AP severity. View Full-Text
Keywords: sphingolipids; acute pancreatitis; ceramide; sphingosine; sphingosine-1-phosphate sphingolipids; acute pancreatitis; ceramide; sphingosine; sphingosine-1-phosphate

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Konończuk, T.; Łukaszuk, B.; Żendzian-Piotrowska, M.; Dąbrowski, A.; Krzyżak, M.; Ostrowska, L.; Kurek, K. Plasma Sphingolipids in Acute Pancreatitis. Int. J. Mol. Sci. 2017, 18, 2606.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top